Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer

P and T

Volumn 31, Issue 10, 2006, Pages

  Gosselin, Antoine ^a   McKenzie, R Scott ^b   Lefebvre, Patrick ^a   Mody, Samir H ^b   Piech, Catherine Tak ^b   Duh, Mei Sheng ^c  

^a GROUPE D ANALYSE   (Canada)

^b Ortho Biotech Products LP   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

Area under the curve; Chemotherapy induced anemia; Darbepoetin alfa; Dose conversion ratio; Epoetin alfa

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TREATMENT OUTCOME;

EID: 33750472338     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Beveridge RA, Rifkin RM, Moleski RJ, et al. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy 2003;23(12 Part 2):101S-109S.
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91(19):1616-1634.
3. Cella D, Bron D. The effect of epoetin alfa on quality of life in anemic cancer patients. Cancer Practice 1999;7(4):177-182.
4. Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 1998;25(3 Suppl 7):43-46.
5. Heymann SJ, Brewer TF. The infectious risks of transfusions in the United States: A decision-analytic approach. Am J Infect Control 1993;21(4):174-182.
6. Bux J. Transfusion-related acute lung injury (TRALI): A serious adverse event of blood transfusion. Vox Sang 2005;89(1):1-10.
7. Gajic O, Moore SB. Transfusion-related acute lung injury. Mayo Clin Proc 2005;80(6):766-770.
8. Epoetin alfa (Procrit), product package insert Available at: www. procrit.com/common/prescribing_information/PROCRIT/PDF/ProcritBooklet.pdf. Accessed January 1, 2006.
9. Darbepoetin alfa (Aranesp), product package insert. Available at: www.aranesp.com/pdf/aranesp_PI.pdf. Accessed January 1, 2006.
10. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 22. Electronic version, September 27, 2004, 10.1200/JCO.2004.10.020.
11. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19(11):2875-2882.
12. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16(10):3412-3425.
13. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes of patients with nonmyeloid malignancies during cancer chemotherapy in community practice. J Clin Oncol 1997;15(3):1218-1234.
14. Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1(2):131-138.
15. Vansteenkiste J, Pirker R, Massuri B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94(16):1211- 1220.
16. Valley AW. Overview of cancer-related anemia: Focus on the potential role of darbepoetin alfa. Pharmacotherapy 2002;(9 Pt 2):22:150S-159S.
17. Cable R, Carlson B, Chambers L, et al. Practice Guidelines for Blood Transfusion: A Compilation from Recent Peer-Reviewed Literature. American National Red Cross. Available at: http://chapters.redcross.org/br/indianaoh/ files/pgbtscreen.pdf. Accessed January 11, 2006.
18. Schwartzberg L, Shiffman R, Tomita D, et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 2003;25(11):2781-2796.
19. Herrington JD, Davidson SL, Tomita DK, et al. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm 2005;62(1):54-62.
20. Glaspy J, Jadeja J, Justice G, et al. Darbepoetin alfa administered every 1 or 2 weeks (with no loss of dose efficiency) alleviates anemia in patients with solid tumors. Blood 2001;98(11):298a (Abstract No. 1256).
21. Poster, American Society of Hematology, 43rd Annual Meeting, Orlando, FL, December 7-11, 2001.
22. Glaspy J, Jadeja J, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-276.
23. Scott S. Dose conversion from recombinant human erythropoietin to darbepoetin alfa. Pharmacotherapy 2002;22(9 Part 2):160S-165S.
24. Rosberg JH, Ben-Hamadi R, Cremieux PY, et al. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: A meta-analysis. Clin Drug Invest 2005;25(1):33-48.
25. Federal Register. Vol. 67, No. 212, November 1, 2002. Rules and Regulations, pp 66757-66759. Available at: http://frwebgate.access.gpo.gov/cgi- bin/getdoc.cgi?dbname=2002_register&docid=page+66717-66766.pdf. Accessed June 29, 2006.
26. Federal Register. Vol. 68, No. 216. November 7, 2003. Rules and Regulations, pp 63455-63457. Available at: http://a257.g. akamaitech.net/7/257/ 2422/14mar20010800/edocket.access.gpo. gov/2003/pdf/03-27791.pdf. Accessed June 29, 2006.
27. Federal Register. Vol. 69, No. 219. November 15, 2004. Rules and Regulations, pp 65796-65797. Available at: http://a257.g. akamaitech.net/7/257/ 2422/06jun20041800/edocket.access.gpo.g ov/2004/04-24759.htm. Accessed June 29, 2006.
28. Duh MS, Lefebvre P, Fastenau J, et al. Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve. The Oncologist 2005;10:438-448.
29. Waltzman R, Croot C, Williams D. Final hematologic results: Epoetin alfa 40,000 U QW vs. darbepoetin alfa 200 meg Q2W in anemic cancer patients receiving chemotherapy. Annu Meet Proc 2005;24 (Abstract No. 8153).
30. Poster, American Society for Clinical Oncology, 41st Annual Meeting, Orlando, FL, May 13-17, 2005.
31. Waltzman R, Croot C, Justice G, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. The Oncologist 2005;10:642-650.
32. Sabbatini P, Cella D, Chanan-Khan A, et al. Cancer and treatment-related anemia. In: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, v.2.2004. Available at: www.nccn.org. Accessed January 12, 2006.
33. Rizzo JD, Iichtin AE, Woolf SH, et al. Use of epoetin alfa in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
34. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: Issues in the design and analysis of stochastic cost effectiveness studies in health care. Med Care 1994;32:160-163.
35. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.
36. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40(1):110-118.
37. Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003;18:362-369.
38. Brunkhorst R, Bommer J, Braun J, et al. Darbepoetin alfa effectively maintains haemoglobin concentration at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004;19:1224-1230.
39. Campos SM, Duh MS, Lefebvre P, Rosberg J. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Cancer Network 2005;3(6):807-816.
40. Glaspy J, Berg R, Tomita D, et al., on behalf of the 20030125 Study Group. Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 meg every 2 weeks versus epoetin alfa 40,000 units weekly in patients with chemotherapy-induced anemia (CIA). Annu Meet Proc 2005;24 (Abstract No. 8125).
41. Poster, American Society for Clinical Oncology, 41st Annual Meeting, May 13-17, 2005, Orlando, FL. J Support Oncol 2005;3(5 Suppl 2):6-7.